Literature DB >> 19782538

Correlation between free and total vancomycin serum concentrations in patients treated for Gram-positive infections.

Karine Berthoin1, Els Ampe, Paul M Tulkens, Stephane Carryn.   

Abstract

Routine therapeutic drug monitoring (TDM) reports only total vancomycin (VAN) concentrations, although protein binding varies and it is generally accepted that only free VAN is active. The aims of this study were to examine the correlation between free and total VAN concentrations in order to estimate whether free VAN levels can be predicted based on its total concentration. A high-performance liquid chromatography (HPLC) method was set up and validated (against routine laboratory immunoassays) for measurement of free [ultrafiltration (Centrifree); cut-off 30 kDa] and total [solid-phase extraction (Oasis MCX cartridge)] VAN in serum. Samples (n=65) from patients (n=15) treated by continuous infusion were analysed. There was a wide variation in free to total VAN ratios [range 12-100%; mean 63.6+/-25.8%, with 59 values falling outside the 95% confidence interval (57.3-69.9%); median 70.2%]. The correlation between free and total VAN was poor (R(2)=0.55). Artefacts such as pH variation of sera could be excluded. Both intrapatient and interpatient variabilities were large and no correlation could be made with patients' clinical conditions. Total VAN concentration is not predictive of free VAN concentration, suggesting that actual determination of free VAN might be recommended as an improved method of TDM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19782538     DOI: 10.1016/j.ijantimicag.2009.08.005

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  20 in total

1.  Preparation and antibiotic drug release of mineralized collagen coatings on titanium.

Authors:  Junjun Tu; Mengfei Yu; Yan Lu; Kui Cheng; Wenjian Weng; Jun Lin; Huiming Wang; Piyi Du; Gaorong Han
Journal:  J Mater Sci Mater Med       Date:  2012-06-06       Impact factor: 3.896

2.  Traditional weight-based vancomycin dosing is inadequate in critically ill trauma patients.

Authors:  D D Yeh; M E Kutcher; K Lunghi
Journal:  Eur J Trauma Emerg Surg       Date:  2011-11-15       Impact factor: 3.693

3.  Preferential emergence of reduced vancomycin susceptibility in health care-associated methicillin-resistant Staphylococcus aureus isolates during continuous-infusion vancomycin therapy in an in vitro dynamic model.

Authors:  Sheryl Zelenitsky; Noha Alkurdi; Zhanni Weber; Robert Ariano; George Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

4.  Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding.

Authors:  Jill M Butterfield; Nimish Patel; Manjunath P Pai; Thomas G Rosano; George L Drusano; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

5.  Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients.

Authors:  Kim Vanstraelen; Joost Wauters; Ine Vercammen; Henriette de Loor; Johan Maertens; Katrien Lagrou; Pieter Annaert; Isabel Spriet
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

6.  Study of macrophage functions in murine J774 cells and human activated THP-1 cells exposed to oritavancin, a lipoglycopeptide with high cellular accumulation.

Authors:  Sandrine Lemaire; Marie-Paule Mingeot-Leclercq; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2014-01-21       Impact factor: 5.191

7.  External Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: The transferability of published models to different clinical settings.

Authors:  Wei Zhao; Florentia Kaguelidou; Valérie Biran; Daolun Zhang; Karel Allegaert; Edmund V Capparelli; Nick Holford; Toshimi Kimura; Yoke-Lin Lo; José-Esteban Peris; Alison Thomson; John N van den Anker; May Fakhoury; Evelyne Jacqz-Aigrain
Journal:  Br J Clin Pharmacol       Date:  2013-04       Impact factor: 4.335

8.  Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.

Authors:  Jared L Crandon; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2010-09-13       Impact factor: 5.191

9.  Association between vancomycin trough concentration and area under the concentration-time curve in neonates.

Authors:  Adam Frymoyer; Adam L Hersh; Mohammed H El-Komy; Shabnam Gaskari; Felice Su; David R Drover; Krisa Van Meurs
Journal:  Antimicrob Agents Chemother       Date:  2014-08-18       Impact factor: 5.191

10.  Factors impacting unbound vancomycin concentrations in neonates and young infants.

Authors:  Anne Smits; Steven Pauwels; Matthijs Oyaert; Nele Peersman; Isabel Spriet; Veroniek Saegeman; Karel Allegaert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-05-16       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.